• Histone H4K12 Lactylation Drives TNBC via SLFN5 Suppression

  2026-08-05

  This study reveals that histone H4K12 lactylation, induced by elevated lactate in triple-negative breast cancer (TNBC), promotes tumor progression by downregulating the tumor suppressor SLFN5. It establishes a mechanistic link between tumor metabolism and epigenetic reprogramming, and demonstrates that inhibiting lactate production—using metabolic inhibitors such as sodium oxamate—can reverse this malignancy-driving axis.

• Pharmacological Induction of Embryonic Dormancy via mTOR Inh

  2026-08-05

  This article summarizes a protocol for inducing a reversible, dormancy-like state in mammalian embryonic cells and pluripotent stem cells using pharmacological mTOR inhibition. The approach enables noninvasive, scalable studies of diapause and cellular dormancy, with implications for reproductive biology and developmental research.

• β-Elemene Suppresses Adipogenesis via AMPK Activation in 3T3

  2026-08-04

  This study demonstrates that β-Elemene inhibits adipogenesis in 3T3-L1 preadipocytes by activating the AMPK pathway, reversing insulin resistance-induced lipid accumulation. These findings highlight β-Elemene's potential as a molecular tool for probing obesity mechanisms and developing metabolic research models.

• WY-14643 (Pirinixic Acid): Applied Workflows in Metabolic Re

  2026-08-04

  WY-14643 (Pirinixic Acid) stands out as a selective PPARα agonist, streamlining advanced metabolic and inflammation studies with robust reproducibility. This guide translates cutting-edge research into practical protocols, troubleshooting strategies, and assay enhancements for metabolic disorder and tumor microenvironment research.

• Dronedarone (Multaq): Mechanistic Insights for AF Research

  2026-08-03

  Explore the molecular mechanisms and research applications of Dronedarone (Multaq) as an antiarrhythmic agent for atrial fibrillation. This article delivers unique analytical depth, bridging pharmacological action with advanced assay design.

• PP2A-Mediated Autophagy Drives Drug Resistance in Candida Bi

  2026-08-03

  The referenced study reveals how protein phosphatase 2A (PP2A) modulates autophagy and biofilm-associated drug resistance in Candida albicans. By dissecting the phosphorylation of key ATG proteins, the work highlights a potential regulatory axis for overcoming antifungal resistance, informing future antifungal strategies and biofilm research.

• Innovative In Vitro Metrics for Cancer Drug Response Evaluat

  2026-08-02

  The referenced dissertation introduces a refined framework for evaluating anti-cancer drug responses in vitro, distinguishing between cell proliferation arrest and cell death using relative and fractional viability metrics. This approach enables more precise assessment of drug mechanisms and could improve the translational relevance of preclinical cancer research.

• Lumiracoxib in COX-2 Selective Inhibition Assays: Advanced W

  2026-08-01

  Lumiracoxib empowers researchers to dissect COX-2-mediated pathways in inflammation models with high selectivity and reproducibility. This guide details optimized protocols, troubleshooting, and translational insights from recent muscle ischemia studies, illustrating how precise pathway modulation with Lumiracoxib yields actionable data that can't be achieved with less selective inhibitors.

• FAK Inhibitor 14: Optimized Workflows and Troubleshooting in

  2026-07-31

  FAK Inhibitor 14 (benzene-1,2,4,5-tetraamine tetrahydrochloride) enables precise dissection of FAK signaling in advanced cancer models, including cholesterol-resistant ovarian cancer. This guide delivers protocol enhancements, troubleshooting strategies, and actionable insights to maximize reproducibility and data quality in tumor metastasis research.

• WY-14643 (Pirinixic Acid): Reliable PPARα Agonism in Metabol

  2026-07-31

  This article provides a scenario-driven, evidence-based exploration of WY-14643 (Pirinixic Acid, SKU A4305), emphasizing its reproducibility and validated performance in cell viability, lipid metabolism, and inflammation assays. Researchers will find practical insights, protocol parameters, and comparative guidance to optimize metabolic disorder research using this selective PPARα agonist.

• Cyclic di-GMP: Bridging Bacterial Persistence and Immune Mod

  2026-07-30

  This article provides translational researchers with a mechanistic and strategic perspective on cyclic di-GMP, highlighting its dual role as an intracellular second messenger in bacterial genome stability and mammalian immune modulation. Drawing on newly published evidence, we examine how cyclic di-GMP acts as an antitoxin in biofilm resilience, discuss its activation of STING for cancer immunotherapy, and provide actionable protocol guidance. By synthesizing recent findings and practical workflow recommendations, this piece advances the conversation beyond standard product literature, underscoring the potential of APExBIO's cyclic di-GMP as a unique tool for infection biology and immuno-oncology research.

• YAP-TEAD Mediates PPARα-Induced Liver Regeneration in Mice

  2026-07-30

  This study uncovers the critical role of YAP-TEAD signaling in mediating PPARα-driven hepatomegaly and liver regeneration in murine models. By dissecting genetic dependencies and pharmacological interventions, the work provides mechanistic clarity for targeted metabolic disorder research and regenerative medicine.

• Smurf1 Downregulation Enhances Cisplatin Sensitivity in CRC

  2026-07-29

  This study demonstrates that low Smurf1 expression significantly increases the chemosensitivity of colorectal cancer (CRC) to cisplatin (CDDP) and gemcitabine in both cell-based and patient-derived xenograft models. The findings highlight Smurf1 as a promising molecular target for overcoming chemotherapy resistance in CRC.

• Actinomycin D in Cancer Research: Applied Protocols & Soluti

  2026-07-29

  Actinomycin D (ActD) stands out as a gold-standard transcriptional inhibitor, enabling robust analysis of apoptosis induction and mRNA stability in cancer models. This article delivers evidence-backed workflows, advanced use-cases, and troubleshooting strategies to maximize data reproducibility using APExBIO's Actinomycin D.

• EZ Cap EGFP mRNA 5-moUTP: Streamlining High-Fidelity mRNA Wo

  2026-07-28

  EZ Cap™ EGFP mRNA (5-moUTP) enables robust, immune-evasive protein expression in both in vitro and in vivo settings. Its advanced chemical modifications and Cap 1 structure set a new benchmark for reproducibility, translation efficiency, and real-time imaging applications.

16132 records 1/1076 page Next 12345 下5页 Last page